Biotech Archives - Page 40 of 795

3 minute read

Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease

May 8, 8:12 AM

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared

PRME

1 minute read

Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024

By Benzinga Newsdesk

May 8, 8:04 AM

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of

LPCN

2 minute read

AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines

By Benzinga Neuro

May 8, 6:23 AM

It is worth noting that AstraZeneca has previously conceded in court documents that Vaxzevria can induce side effects such as blood clots and low blood platelet counts.

AZN

2 minute read

CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA

By Benzinga Newsdesk

May 7, 5:26 PM

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform

CTMX

2 minute read

Nano-Cap Eledon Pharmaceuticals’ Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

By Vandana Singh

May 7, 3:40 PM

Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.

ELDN

1 minute read

Johnson & Johnson’s TARIS Platform – Goldman Sachs Outlines Potential For The Bladder Cancer Therapy

By Vandana Singh

May 7, 2:31 PM

Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration and significant revenue potential.

JNJ

1 minute read

What About Eli Lilly’s Drug For Early Alzheimer’s? FDA Panel To Discuss Next Month

By Vandana Singh

May 7, 12:38 PM

FDA's advisory committee meeting on June 10, 2024, discussing Eli Lilly's donanemab for early Alzheimer's.

LLY

2 minute read

“FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month” – Marijuana Moment

By Benzinga Newsdesk

May 7, 11:54 AM

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy

CMPS

2 minute read

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

By Vandana Singh

May 7, 10:20 AM

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024 revenue guidance: $225-$245 million.

ESPR

2 minute read

M8 Pharmaceuticals Signs An Exclusive Licensing Agreement With Supernus Pharmaceuticals To Seek Regulatory Approval And Commercialize Qelbree Under M8’s Trademark In Latin America

By Benzinga Newsdesk

May 7, 10:03 AM

M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ('Supernus'), a biopharmaceutical company focused

SUPN